To the best of our knowledge, this study is the first to confirm that CART-HER2 cells show specific, effective, and persistent tumor-killing activity against HER2-positive primary GC cells and GCSCs in pre-clinical tests. This evidence concerns the gene ERBB2 and gastric cancer.